SCHEMBL1355640

SCHEMBL1355640

CCC(Nc1nc(NCc2ccccc2N)c2ncn(C(C)C)c2n1)C(C)O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 20/20 0.76
CDK7 P50613 15/20 0.76
CCNE1 P24864 14/20 0.76
CCNH P51946 13/20 0.76
CDK9 P50750 13/20 0.76
CDK1 P06493 11/20 0.76
CDK4 P11802 11/20 0.76
CCNB1 P14635 9/20 0.76
MAPK1 P28482 8/20 0.76
CCND1 P24385 7/20 0.76
CDK5 Q00535 7/20 0.76
CCNT1 O60563 8/20 0.70
CDK5R1 Q15078 5/20 0.70
CCNT2 O60583 1/20 0.68
CCNB2 O95067 1/20 0.68
CCNE2 O96020 1/20 0.68
CCNB3 Q8WWL7 1/20 0.68
MNAT1 P51948 1/20 0.68
CDK6 Q00534 1/20 0.68
CASK O14936 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1354578 0.90 CDK2 (0.61) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1353646 0.89 CDK2 (0.60) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1354155 0.88 CDK2 (0.70) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1355013 0.88 CDK2 (0.71) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1352461 0.88 CDK2 (0.70) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1354640 0.88 CDK1 (0.81) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1353640 0.88 CDK2 (0.82) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1355411 0.88 CDK2 (0.82) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1355669 0.88 CDK2 (0.67) CDK2CDK7CCNE1CCNHCDK9
SCHEMBL1352423 0.87 CDK2 (0.81) CDK2CDK7CCNE1CCNHCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391626-B1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2014-10-01 EP claimed
EP-2391626-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2011-12-07 EP claimed
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2011-11-24 US claimed
WO-2010085924-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2010-08-05 WO claimed
US-9023857-B2 Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2015-05-05 US disclosed
EP-2391626-B1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2014-10-01 EP disclosed
EP-2391626-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2011-12-07 EP disclosed
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2011-11-24 US disclosed
WO-2010085924-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS CDK6, CCNI, CDK2 CDK2 3/4885CDK7 9/4885CCNE1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.